CTOs on the Move

BG Medicine, Inc.

www.bg-medicine.com

 
BG Medicine, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Waltham, MA. To find more information about BG Medicine, Inc., please visit www.bg-medicine.com
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Health Integrated

Health Integrated leads the industry with Precision Empowered Care Management, enabling health plans to precisely manage their most vulnerable members. By combining actionable big data with a proven biopsychosocial model, we address the physical, psychological and social drivers impacting member health and satisfaction. As a result, plans enhance quality, achieve compliance and strengthen their financial performance, while empowering members to achieve better outcomes.

Peerfit

Peerfit connects employers, brokers and insurance carriers to local fitness experiences.

Radiology Associates of Macon

Radiology Associates of Macon is a Macon, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NutriSavings

NutriSavings mission is to reduce the cost of healthcare by educating employees on healthy eating and rewarding good food choices with savings at the supermarket, grocery store, or farmers market. NutriSavings is a joint venture between Edenred (NYSE Euronext), the world leader in corporate services, and SavingStar, the only national fully digital grocery savings service in the US.

MolecularMD

MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.